Inovio Plans BLA Submission for INO-3107 Amid Financial Adjustments

Published 1 hours agoINO

Inovio Plans BLA Submission for INO-3107 Amid Financial Adjustments

Inovio Pharmaceuticals is moving forward with the submission of its Biologics License Application (BLA) for INO-3107 following the resolution of a manufacturing issue with its CELLECTRA device. The company has scheduled to initiate the rolling submission in mid-2025, with an aim to complete it by the second half of the same year. Inovio intends for the BLA to be accepted for priority review by the close of 2025, according to their latest announcements.

Financially, Inovio reported having $94.1 million in cash at the end of 2024, down from $145.3 million the previous year. Despite this decrease, the company is projecting that its cash reserves will sustain operations into the first quarter of 2026. The anticipated net cash burn for the initial quarter of 2025 is estimated at around $27 million, as noted by Nasdaq.

Apart from the BLA progress, Inovio continues to advance its DNA medicine pipeline, which includes promising developments in areas such as recurrent respiratory papillomatosis with INO-3107 and DNA-encoded monoclonal antibodies for COVID-19. The company is also pushing forward INO-3112 for HPV-related cancers, underscoring its strategic focus on innovative DNA-based therapeutics.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Vaxart Secures Funding and Advances Vaccine Trials

Vaxart Secures Funding and Advances Vaccine Trials

2 minutes agoVXRT

Vaxart, Inc., a biotech company known for its innovative vaccine programs, has announced that it has secured sufficient funding to extend its operational cash runway into the first quarter of 2026. This financial boost is critical for sustaining the development of its vaccine initiatives and ensuring ongoing operations in the years to come. In addition to its bolstered financial position, Vaxart is making strides with its oral COVID-19 vaccine program. The company is preparing for a substantial Phase 2b clinical trial that will involve 10,000 participants and will compare the efficacy of its oral vaccine candidate against an existing mRNA vaccine. This trial represents a significant step forward in the COVID-19 vaccine landscape. Also, Vaxart is advancing its oral norovirus vaccine, having recently started a Phase 1 trial focused on lactating mothers and reporting positive Phase 2 trial results that demonstrate strong immunogenicity and a favorable safety profile. These developments highlight Vaxart’s ongoing commitment to its vaccine pipeline while ensuring a stable financial footing. As Reuters reported, these strategic moves come at a time when the company's stock price is hovering around $0.4155, with recent trading activity indicating a slight change of $0.01 (0.02%) from the prior closing price. Vaxart continues to navigate a competitive market, marked by a recent intraday high of $0.4799.

Pixelworks Targets Shanghai Subsidiary Profitability with Strategic Initiatives

Pixelworks Targets Shanghai Subsidiary Profitability with Strategic Initiatives

1 hours agoPXLW

Pixelworks has unveiled a series of strategic moves designed to boost the profitability of its Shanghai subsidiary and enhance its TrueCut Motion platform. These initiatives include a 10% reduction in operating expenses as part of broader cost-saving measures, which the company expects to be fully realized by the end of the second quarter of 2025. Pixelworks Shanghai has also earned the "Little Giant" certification from China's Ministry of Industry and Information Technology. This prestigious designation not only signifies recognition as a leading enterprise with significant growth potential but also opens doors to government subsidies. Additionally, Pixelworks secured a multi-year deal with Universal Pictures to incorporate its TrueCut Motion technology into upcoming theatrical releases, aiming to improve visual effects and boost revenue. The company is actively assessing strategic options for its Shanghai unit through a comprehensive review process, exploring various ownership and collaboration structures. These efforts collectively aim to position Pixelworks Shanghai for sustained growth and profitability by 2025. Reuters reported that these initiatives are part of Pixelworks' broader strategy to maximize long-term growth and shareholder value.

Inovio Plans BLA Submission for INO-3107 Amid Financial Adjustments

Inovio Plans BLA Submission for INO-3107 Amid Financial Adjustments

Inovio Pharmaceuticals is moving forward with the submission of its Biologics License Application (BLA) for INO-3107 following the resolution of a manufacturing issue with its CELLECTRA device. The company has scheduled to initiate the rolling submission in mid-2025, with an aim to complete it by the second half of the same year. Inovio intends for the BLA to be accepted for priority review by the close of 2025, according to their latest announcements. Financially, Inovio reported having $94.1 million in cash at the end of 2024, down from $145.3 million the previous year. Despite this decrease, the company is projecting that its cash reserves will sustain operations into the first quarter of 2026. The anticipated net cash burn for the initial quarter of 2025 is estimated at around $27 million, as noted by Nasdaq. Apart from the BLA progress, Inovio continues to advance its DNA medicine pipeline, which includes promising developments in areas such as recurrent respiratory papillomatosis with INO-3107 and DNA-encoded monoclonal antibodies for COVID-19. The company is also pushing forward INO-3112 for HPV-related cancers, underscoring its strategic focus on innovative DNA-based therapeutics.

Disney Embraces Bundling to Boost Streaming Success

Disney Embraces Bundling to Boost Streaming Success

Dana Walden, Co-Chair of Disney Entertainment, has laid out Disney's strategic approach to bolstering its streaming services. This involves offering bundled packages that combine Disney+, Hulu, and ESPN+ at discounted rates. The strategy has effectively increased subscriber numbers and improved retention, as shown by a bundle featuring Warner Bros. Discovery's Max that achieved an 80% retention rate over three months, exceeding the rates when services are subscribed individually, as detailed by StreamTV Insider. Furthermore, Disney is integrating its streaming platforms with traditional linear TV through key partnerships. One significant collaboration is with Charter Communications, where ad-supported versions of Disney+ and ESPN+ are offered within certain cable plans. This approach is intended to tap into existing linear TV audiences, thus broadening the reach of Disney's streaming services, as reported by The Current. Disney's strategy also includes content sharing between its linear TV networks and streaming platforms. Popular shows like "Grey's Anatomy" and "Abbott Elementary" air on ABC and are quickly made available on Hulu, broadening the audience and optimizing content distribution costs. The company is leveraging its robust content library and strategic partnerships to increase its streaming subscriber growth and advertising revenue, illustrating Disney's commitment to expanding its digital footprint.